Exploration of Circular RNA in B-cell Hematologic Malignancies

This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with R/R B-cell malignancies.

Trial Details

NCT ID

NCT07774572

Phase

PHASE1

Sponsor

Ruijin Hospital

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Investigational product (IP)

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806
Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

Age ≥ 18 years, any gender.
Able to provide written informed consent.
Confirmed diagnosis of relapsed/refractory (R/R) CD19-positive B-cell malignancy, including:
Diffuse large B-cell lymphoma (DLBCL)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →